繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 甲亢病 >> 药品推荐 >> 盐酸西那卡塞片|MIMPARA(Cinacalcet Hydrochloride tablet)

盐酸西那卡塞片|MIMPARA(Cinacalcet Hydrochloride tablet)

2014-06-14 16:06:09  作者:新特药房  来源:互联网  浏览次数:342  文字大小:【】【】【
简介: 部分中文Mimpara处方资料(仅供参考)【药品名称】通用名称:盐酸西那卡塞片商品名称:Sensipar,Mimpara,Regpara 英文名称:Cinacalcet Hydrochloride Tablet【成份】化学名称:N-((1R)-1-(1-萘基)乙 ...

部分中文Mimpara处方资料(仅供参考)
【药品名称】
通用名称:盐酸西那卡塞片
商品名称:Sensipar,Mimpara,Regpara
英文名称:Cinacalcet Hydrochloride Tablet
【成份】
化学名称:
N-((1R)-1-(1-萘基)乙基)-3-(3-(三氟甲基)苯基)丙-1-胺盐酸盐; 
分子式: C22H22F3N.HCl ;    
分子量:393.87
【适应症】
该药主要用于治疗肾病透析患者的继发性甲状旁腺机能亢进,或者甲状旁腺癌所致的高钙血症。
【用法用量】
该药应整片吞服,初始剂量为30mg/天,进食时服用。随后根据患者反应情况,每2~4周调整一次剂量(按60mg/天、90mg/天、120mg/天和180mg/天顺序依次递增),直至患者PTH水平达到美国肾脏基金会临床指南推荐的标准(150~300pg/ml)。该药可单独应用或与维生素D醇和磷酸盐结合剂合用。
【患者咨询】
服用该药期间,患者应避免怀孕或哺乳。许多药物可能与该药产生药物相互作用,因此服用该药时应尽量停用其他药物,包括非处方药和营养补充剂。提醒患者在出现下述不良反应时,应尽快与医师联系,并采取相应治疗措施。这些不良反应包括:腹部痉挛或疼痛;面部、口唇、舌头和手足出现烧灼感、麻痹、刺痛、瘙痒或麻刺感;背部或腿部出现痛性痉挛;抑郁;意识错乱;吞咽或呼吸困难;幻觉;易怒;面肌抽搐;肌痛或癫痫发作。
Mimpara
1. Name of the medicinal product
Mimpara® 30 mg film-coated tablets.
Mimpara® 60 mg film-coated tablets.
Mimpara® 90 mg film-coated tablets.
2. Qualitative and quantitative composition
Each tablet contains 30 mg cinacalcet (as hydrochloride).
Each tablet contains 60 mg cinacalcet (as hydrochloride).
Each tablet contains 90 mg cinacalcet (as hydrochloride).
Excipient with known effect:
Each 30 mg tablet contains 2.74 mg of lactose.
Each 60 mg tablet contains 5.47 mg of lactose.
Each 90 mg tablet contains 8.21 mg of lactose.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Film-coated tablet (tablet).
Light green, oval, film-coated tablet marked “AMG” on one side and “30” on the other.
Light green, oval, film-coated tablet marked “AMG” on one side and “60” on the other.
Light green, oval, film-coated tablet marked “AMG” on one side and “90” on the other.
4. Clinical particulars
4.1 Therapeutic indications
Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.
Mimpara may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate (see section 5.1).
Reduction of hypercalcaemia in patients with:
• parathyroid carcinoma.
• primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
4.2 Posology and method of administration
Secondary hyperparathyroidism
Adults and elderly (> 65 years)
The recommended starting dose for adults is 30 mg once per day. Mimpara should be titrated every 2 to 4 weeks to a maximum dose of 180 mg once daily to achieve a target parathyroid hormone (PTH) in dialysis patients of between 150-300 pg/ml (15.9-31.8 pmol/l) in the intact PTH (iPTH) assay. PTH levels should be assessed at least 12 hours after dosing with Mimpara. Reference should be made to current treatment guidelines.
PTH should be measured 1 to 4 weeks after initiation or dose adjustment of Mimpara. PTH should be monitored approximately every 1-3 months during maintenance. Either the intact PTH (iPTH) or bio-intact PTH (biPTH) may be used to measure PTH levels; treatment with Mimpara does not alter the relationship between iPTH and biPTH.
During dose titration, serum calcium levels should be monitored frequently, and within 1 week of initiation or dose adjustment of Mimpara. Once the maintenance dose has been established, serum calcium should be measured approximately monthly. If serum calcium levels decrease below the normal range, appropriate steps should be taken, including adjustment of concomitant therapy (see section 4.4).
Children and adolescents
Mimpara is not indicated for use in children and adolescents due to a lack of data on safety and efficacy (see section 4.4).
Parathyroid carcinoma and primary hyperparathyroidism
Adults and elderly (> 65 years)
The recommended starting dose of Mimpara for adults is 30 mg twice per day. The dose of Mimpara should be titrated every 2 to 4 weeks through sequential doses of 30 mg twice daily, 60 mg twice daily, 90 mg twice daily, and 90 mg three or four times daily as necessary to reduce serum calcium concentration to or below the upper limit of normal. The maximum dose used in clinical trials was 90 mg four times daily.
Serum calcium should be measured within 1 week after initiation or dose adjustment of Mimpara. Once maintenance dose levels have been established, serum calcium should be measured every 2 to 3 months. After titration to the maximum dose of Mimpara, serum calcium should be periodically monitored; if clinically relevant reductions in serum calcium are not maintained, discontinuation of Mimpara therapy should be considered (see section 5.1).
Children and adolescents
Mimpara is not indicated for use in children and adolescents due to a lack of data on safety and efficacy (see section 4.4).
Hepatic impairment
No change in starting dose is necessary. Mimpara should be used with caution in patients with moderate to severe hepatic impairment and treatment should be closely monitored during dose titration and continued treatment (see sections 4.4 and 5.2).
Method of administration
For oral use. It is recommended that Mimpara be taken with food or shortly after a meal, as studies have shown that bioavailability of cinacalcet is increased when taken with food (see section 5.2). Tablets should be taken whole and not divided.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use
Serum calcium
Mimpara treatment should not be initiated in patients with a serum calcium (corrected for albumin) below the lower limit of the normal range.
Life threatening events and fatal outcomes associated with hypocalcaemia have been reported in adult and paediatric patients treated with Mimpara. Manifestations of hypocalcaemia may include paraesthesias, myalgias, cramping, tetany and convulsions. Decreases in serum calcium can also prolong the QT interval, potentially resulting in ventricular arrhythmia secondary to hypocalcaemia. Cases of QT prolongation and ventricular arrhythmia have been reported in patients treated with cinacalcet (see section 4.8). Caution is advised in patients with other risk factors for QT prolongation such as patients with known congenital long QT syndrome or patients receiving medicinal products known to cause QT prolongation.
Since cinacalcet lowers serum calcium, patients should be monitored carefully for the occurrence of hypocalcaemia (see section 4.2). Serum calcium should be measured within 1 week after initiation or dose adjustment of Mimpara. Once the maintenance dose has been established, serum calcium should be measured approximately monthly.
In the event that serum calcium levels fall below 8.4 mg/dl (2.1 mmol/l) and/or symptoms of hypocalcaemia occur the following management is recommended:

Serum calcium value or clinical symptoms of hypocalcaemia

Recommendations

< 8.4 mg/dl (2.1 mmol/l) and>7.5 mg/dl (1.9 mmol/l), or in the presence of clinical symptoms of hypocalcaemia

Calcium-containing phosphate binders, vitamin D sterols and/or adjustment of dialysis fluid calcium concentrations can be used to raise serum calcium according to clinical judgment.

< 8.4 mg/dl (2.1 mmol/l) and > 7.5 mg/dl (1.9 mmol/l) or persistent symptoms of hypocalcaemia despite attempts to increase serum calcium

Reduce or withhold dose of Mimpara.

≤ 7.5 mg/dl (1.9 mmol/l) or persistent symptoms of hypocalcemia and Vitamin D cannot be increased

Withhold administration of Mimpara until serum calcium levels reach 8.0 mg/dl (2.0 mmol/l) and/or symptoms of hypocalcaemia have resolved.

Treatment should be reinitiated using the next lowest dose of Mimpara.


In CKD patients receiving dialysis who were administered Mimpara, approximately 30% of patients had at least one serum calcium value less than 7.5 mg/dl (1.9 mmol/l).
Cinacalcet is not indicated for CKD patients not on dialysis. Investigational studies have shown that CKD patients not on dialysis treated with cinacalcet have an increased risk for hypocalcaemia (serum calcium levels < 8.4 mg/dl [2.1 mmol/l]) compared with cinacalcet-treated CKD patients on dialysis, which may be due to lower baseline calcium levels and/or the presence of residual kidney function.
Seizures
In clinical studies seizures were observed in 1.4% of Mimpara treated patients and 0.7% of placebo-treated patients. While the basis for the reported difference in seizure rate is not clear, the threshold for seizures is lowered by significant reductions in serum calcium levels.
Hypotension and/or worsening heart failure
In post-marketing safety surveillance, isolated, idiosyncratic cases of hypotension and/or worsening heart failure have been reported in patients with impaired cardiac function, in which a causal relationship to cinacalcet could not be completely excluded and may be mediated by reductions in serum calcium levels. Clinical trial data showed hypotension occurred in 7% of cinacalcet-treated patients, 12% of placebo-treated patients, and heart failure occurred in 2% of patients receiving cinacalcet or placebo.
General
Adynamic bone disease may develop if PTH levels are chronically suppressed below approximately 1.5 times the upper limit of normal with the iPTH assay. If PTH levels decrease below the recommended target range in patients treated with Mimpara, the dose of Mimpara and/or vitamin D sterols should be reduced or therapy discontinued.
Testosterone levels
Testosterone levels are often below the normal range in patients with end-stage renal disease. In a clinical study of ESRD patients on dialysis, free testosterone levels decreased by a median of 31.3% in the Mimpara-treated patients and by 16.3% in the placebo-treated patients after 6 months of treatment. An open-label extension of this study showed no further reductions in free and total testosterone concentrations over a period of 3 years in Mimpara-treated patients. The clinical significance of these reductions in serum testosterone is unknown.
Hepatic impairment
Due to the potential for 2 to 4 fold higher plasma levels of cinacalcet in patients with moderate to severe hepatic impairment (Child-Pugh classification), Mimpara should be used with caution in these patients and treatment should be closely monitored (see sections 4.2 and 5.2).
Lactose
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
Effect of other medications on cinacalcet
Cinacalcet is metabolised in part by the enzyme CYP3A4. Co-administration of 200 mg bid ketoconazole, a strong inhibitor of CYP3A4, caused an approximate 2-fold increase in cinacalcet levels. Dose adjustment of Mimpara may be required if a patient receiving Mimpara initiates or discontinues therapy with a strong inhibitor (e.g. ketoconazole, itraconazole, telithromycin, voriconazole, ritonavir) or inducer (eg rifampicin) of this enzyme (see section 4.4).
In vitro data indicate that cinacalcet is in part metabolised by CYP1A2. Smoking induces CYP1A2; the clearance of cinacalcet was observed to be 36-38% higher in smokers than non-smokers. The effect of CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin) on cinacalcet plasma levels has not been studied. Dose adjustment may be necessary if a patient starts or stops smoking or when concomitant treatment with strong CYP1A2 inhibitors is initiated or discontinued.
Calcium carbonate: Co-administration of calcium carbonate (single 1,500 mg dose) did not alter the pharmacokinetics of cinacalcet.
Sevelamer: Co-administration of sevelamer (2400 mg tid) did not affect the pharmacokinetics of cinacalcet.
Pantoprazole: Co-administration of pantoprazole (80 mg od) did not alter the pharmacokinetics of cinacalcet.
Effect of cinacalcet on other medications
Medicinal products metabolised by the enzyme P450 2D6 (CYP2D6): Cinacalcet is a strong inhibitor of CYP2D6. Dose adjustments of concomitant medicinal products may be required when Mimpara is administered with individually titrated, narrow therapeutic index substances that are predominantly metabolised by CYP2D6 (e.g., flecainide, propafenone, metoprolol, desipramine, nortriptyline, clomipramine) (see section 4.4).
Desipramine: Concurrent administration of 90 mg cinacalcet once daily with 50 mg desipramine, a tricyclic antidepressant metabolised primarily by CYP2D6, significantly increased desipramine exposure 3.6-fold (90 % CI 3.0, 4.4) in CYP2D6 extensive metabolisers.
Warfarin: Multiple oral doses of cinacalcet did not affect the pharmacokinetics or pharmacodynamics (as measured by prothrombin time and clotting factor VII) of warfarin.
The lack of effect of cinacalcet on the pharmacokinetics of R-and S-warfarin and the absence of auto-induction upon multiple dosing in patients indicates that cinacalcet is not an inducer of CYP3A4, CYP1A2 or CYP2C9 in humans.
Midazolam: Co-administration of cinacalcet (90 mg) with orally administered midazolam (2 mg), a CYP3A4 and CYP3A5 substrate, did not alter the pharmacokinetics of midazolam. These data suggest that cinacalcet would not affect the pharmacokinetics of those classes of medicines that are metabolized by CYP3A4 and CYP3A5, such as certain immunosuppressants, including cyclosporine and tacrolimus.
4.6 Fertility, pregnancy and lactation
 Pregnancy
There are no clinical data from the use of cinacalcet in pregnant women. Animal studies do not indicate direct harmful effects with respect to pregnancy, parturition or postnatal development. No embryonal/foetal toxicities were seen in studies in pregnant rats and rabbits with the exception of decreased foetal body weights in rats at doses associated with maternal toxicities (see section 5.3). Mimpara should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Breast-feeding
It is not known whether cinacalcet is excreted in human milk. Cinacalcet is excreted in the milk of lactating rats with a high milk to plasma ratio. Following careful benefit/risk assessment, a decision should be made to discontinue either breast-feeding or treatment with Mimpara.
Fertility
There are no clinical data relating to the effect of cinacalcet on fertility. There were no effects on fertility in animal studies.
4.7 Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed. However, certain adverse reactions may affect the ability to drive and use machines (see section 4.8).
4.8 Undesirable effects
a) Summary of the safety profile
Secondary hyperparathyroidism, parathyroid carcinoma and primary hyperparathyroidism
Based on available data from patients receiving cinacalcet in placebo controlled studies and single-arm studies the most commonly reported adverse reactions were nausea and vomiting. Nausea and vomiting were mild to moderate in severity and transient in nature in the majority of patients. Discontinuation of therapy as a result of undesirable effects was mainly due to nausea and vomiting.
b) Tabulated list of adverse reactions
Adverse reactions, considered at least possibly attributable to cinacalcet treatment in the placebo controlled studies and single-arm studies based on best-evidence assessment of causality are listed below using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000).
Incidence of adverse reactions from controlled clinical studies and post-marketing experience are:

 

MedDRA system organ class

Subject incidence

Adverse reaction

Immune system disorders

Common*

Hypersensitivity reactions

Metabolism and nutrition disorders

Common

Anorexia

Common

Decreased appetite

Nervous system disorders

Common

Seizures

Common

Dizziness

Common

Paraesthesia

Common

Headache

Cardiac disorders

Not known*

Worsening heart failure

Not known*

QT prolongation and ventricular arrhythmia secondary to hypocalcaemia

Vascular disorders

Common

Hypotension

Respiratory, thoracic and mediastinal disorders

Common

Upper respiratory infection

Common

Dyspnoea

Common

Cough

Gastrointestinal disorders

Very common

Nausea

Very common

Vomiting

Common

Dyspepsia

Common

Diarrhoea

Common

Abdominal pain

Common

Abdominal pain – upper

Common

Constipation

Skin and subcutaneous tissue disorders

Common

Rash

Musculoskeletal and connective tissue disorders

Common

Myalgia

Common

Muscle spasms

General disorders and administration site conditions

Common

Asthenia

Investigations

Common

Hypocalcaemia

Common

Hyperkalaemia

Common

Reduced testosterone levels


†see section 4.4
*see section c
c) Description of selected adverse reactions
Hypersensitivity reactions
Hypersensitivity reactions including angioedema and urticaria have been identified during post-marketing use of Mimpara. The frequencies of the individual preferred terms including angioedema and urticaria cannot be estimated from available data.
Hypotension and/or worsening heart failure
There have been reports of idiosyncratic cases of hypotension and/or worsening heart failure in cinacalcet-treated patients with impaired cardiac function in post-marketing safety surveillance, the frequencies of which cannot be estimated from available data.
QT prolongation and ventricular arrhythmia secondary to hypocalcaemia
QT prolongation and ventricular arrhythmia secondary to hypocalcaemia have been identified during post-marketing use of Mimpara, the frequencies of which cannot be estimated from available data (see section 4.4).
d) Paediatric population
Mimpara is not indicated for use in paediatric patients. The safety and efficacy of Mimpara in the paediatric population have not been established. A fatal outcome was reported in a paediatric clinical trial patient with severe hypocalcaemia (see section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
United Kingdom
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard
Ireland
Pharmacovigilance Section
Irish Medicines Board
Kevin O'Malley House
Earlsfort Centre
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.imb.ie
e-mail: imbpharmacovigilance@imb.ie
4.9 Overdose
Doses titrated up to 300 mg once daily have been safely administered to patients receiving dialysis.
Overdose of Mimpara may lead to hypocalcaemia. In the event of overdose, patients should be monitored for signs and symptoms of hypocalcaemia, and treatment should be symptomatic and supportive. Since cinacalcet is highly protein-bound, haemodialysis is not an effective treatment for overdose.
5. Pharmacological properties
5.1 Pharmacodynamic properties
 Pharmacotherapeutic group: Calcium homeostasis, anti-parathyroid agents. ATC code: H05BX01.
Mechanism of action
The calcium sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulator of PTH secretion. Cinacalcet is a calcimimetic agent which directly lowers PTH levels by increasing the sensitivity of the calcium sensing receptor to extracellular calcium. The reduction in PTH is associated with a concomitant decrease in serum calcium levels.
Reductions in PTH levels correlate with cinacalcet concentration.
After steady state is reached, serum calcium concentrations remain constant over the dosing interval.
Secondary Hyperparathyroidism
Three, 6-month, double-blind, placebo-controlled clinical studies were conducted in ESRD patients with uncontrolled secondary HPT receiving dialysis (n=1136). Demographic and baseline characteristics were representative of the dialysis patient population with secondary HPT. Mean baseline iPTH concentrations across the 3 studies were 733 and 683 pg/ml (77.8 and 72.4 pmol/l) for the cinacalcet and placebo groups, respectively. 66% of patients were receiving vitamin D sterols at study entry, and > 90% were receiving phosphate binders. Significant reductions in iPTH, serum calcium-phosphorus product (Ca x P), calcium, and phosphorus were observed in the cinacalcet treated patients compared with placebo-treated patients receiving standard of care, and the results were consistent across the 3 studies. In each of the studies, the primary endpoint (proportion of patients with an iPTH ≤ 250 pg/ml (≤ 26.5 pmol/l)) was achieved by 41%, 46%, and 35% of patients receiving cinacalcet, compared with 4%, 7%, and 6% of patients receiving placebo. Approximately 60% of cinacalcet-treated patients achieved a ≥ 30% reduction in iPTH levels, and this effect was consistent across the spectrum of baseline iPTH levels. The mean reductions in serum Ca x P, calcium, and phosphorus were 14%, 7% and 8%, respectively.
Reductions in iPTH and Ca x P were maintained for up to 12 months of treatment. Cinacalcet decreased iPTH and Ca x P, calcium and phosphorus levels regardless of baseline iPTH or Ca x P level, dialysis modality (PD versus HD), duration of dialysis, and whether or not vitamin D sterols were administered.
Reductions in PTH were associated with non-significant reductions of bone metabolism markers (bone specific alkaline phosphatase, N-telopeptide, bone turnover and bone fibrosis). In post-hoc analyses of pooled data from 6 and 12 months clinical studies, Kaplan-Meier estimates of bone fracture and parathyroidectomy were lower in the cinacalcet group compared with the control group.
Investigational studies in patients with CKD and secondary HPT not undergoing dialysis indicated that cinacalcet reduced PTH levels to a similar extent as in patients with ESRD and secondary HPT receiving dialysis. However, efficacy, safety, optimal doses and treatment targets have not been established in treatment of predialytic renal failure patients. These studies show that CKD patients not undergoing dialysis treated with cinacalcet have an increased risk for hypocalcaemia compared with cinacalcet-treated ESRD patients receiving dialysis, which may be due to lower baseline calcium levels and/or the presence of residual kidney function.
EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) was a randomized, double-blind clinical study evaluating cinacalcet HCl vs. placebo for the reduction of the risk of all-cause mortality and cardiovascular events in 3,883 patients with secondary HPT and CKD receiving dialysis. The study did not meet its primary objective of demonstrating a reduction in risk of all-cause mortality or cardiovascular events including myocardial infarction, hospitalization for unstable angina, heart failure or peripheral vascular event (HR 0.93; 95% CI: 0.85, 1.02; p = 0.112). After adjusting for baseline characteristics in a secondary analysis, the HR for the primary composite endpoint was 0.88; 95% CI: 0.79, 0.97.
Parathyroid carcinoma and Primary Hyperparathyroidism
In a key study,46 patients (29 with parathyroid carcinoma and 17 with primary HPT (who had failed or had contraindications to parathyroidectomy) received cinacalcet for up to 3 years (mean of 328 days for patients with parathyroid carcinoma and mean of 347 days for patients with primary HPT). Cinacalcet was administered at doses ranging from 30 mg twice daily to 90 mg four times daily. The primary endpoint of the study was a reduction of serum calcium of ≥ 1 mg/dl (≥ 0.25 mmol/l). In patients with parathyroid carcinoma, mean serum calcium declined from 14.1 mg/dl to 12.4 mg/dl (3.5 mmol/l to 3.1 mmol/l), while in patients with primary HPT, serum calcium levels declined from 12.7 mg/dl to 10.4 mg/dl (3.2 mmol/l to 2.6 mmol/l). Eighteen of 29 patients (62 %) with parathyroid carcinoma and 15 of 17 subjects (88 %) with primary HPT achieved a reduction in serum calcium of ≥ 1 mg/dl (≥ 0.25 mmol/l).
5.2 Pharmacokinetic properties
Absorption
After oral administration of Mimpara, maximum plasma cinacalcet concentration is achieved in approximately 2 to 6 hours. Based on between-study comparisons, the absolute bioavailability of cinacalcet in fasted subjects has been estimated to be about 20-25%. Administration of Mimpara with food results in an approximate 50 – 80% increase in cinacalcet bioavailability. Increases in plasma cinacalcet concentration are similar, regardless of the fat content of the meal.
At doses above 200 mg, the absorption was saturated probably due to poor solubility.
Distribution
The volume of distribution is high (approximately 1000 litres), indicating extensive distribution. Cinacalcet is approximately 97% bound to plasma proteins and distributes minimally into red blood cells.
After absorption, cinacalcet concentrations decline in a biphasic fashion with an initial half-life of approximately 6 hours and a terminal half-life of 30 to 40 hours. Steady state levels of cinacalcet are achieved within 7 days with minimal accumulation. The pharmacokinetics of cinacalcet does not change over time.
Biotransformation
Cinacalcet is metabolised by multiple enzymes, predominantly CYP3A4 and CYP1A2 (the contribution of CYP1A2 has not been characterised clinically). The major circulating metabolites are inactive.
Based on in vitro data, cinacalcet is a strong inhibitor of CYP2D6, but is neither an inhibitor of other CYP enzymes at concentrations achieved clinically, including CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP3A4 nor an inducer of CYP1A2, CYP2C19 and CYP3A4.
Elimination
After administration of a 75 mg radiolabelled dose to healthy volunteers, cinacalcet was rapidly and extensively metabolised by oxidation followed by conjugation. Renal excretion of metabolites was the prevalent route of elimination of radioactivity. Approximately 80% of the dose was recovered in the urine and 15% in the faeces.
Linearity/non-linearity
The AUC and Cmax of cinacalcet increase approximately linearly over the dose range of 30 to 180 mg once daily.
Pharmacokinetic/pharmacodynamic relationship(s)
Soon after dosing, PTH begins to decrease until a nadir at approximately 2 to 6 hours post-dose, corresponding with cinacalcet Cmax. Thereafter, as cinacalcet levels begin to decline, PTH levels increase until 12 hours post-dose, and then PTH suppression remains approximately constant to the end of the once-daily dosing interval. PTH levels in Mimpara clinical trials were measured at the end of the dosing interval.
Elderly: There are no clinically relevant differences due to age in the pharmacokinetics of cinacalcet.
Renal Insufficiency: The pharmacokinetic profile of cinacalcet in patients with mild, moderate, and severe renal insufficiency, and those on haemodialysis or peritoneal dialysis is comparable to that in healthy volunteers.
Hepatic Insufficiency: Mild hepatic impairment did not notably affect the pharmacokinetics of cinacalcet. Compared to subjects with normal liver function, average AUC of cinacalcet was approximately 2-fold higher in subjects with moderate impairment and approximately 4-fold higher in subjects with severe impairment. The mean half-life of cinacalcet is prolonged by 33% and 70% in patients with moderate and severe hepatic impairment, respectively. Protein binding of cinacalcet is not affected by impaired hepatic function. Because doses are titrated for each subject based on safety and efficacy parameters, no additional dose adjustment is necessary for subjects with hepatic impairment (see sections 4.2 and 4.4).
Gender: Clearance of cinacalcet may be lower in women than in men. Because doses are titrated for each subject, no additional dose adjustment is necessary based on gender.
Paediatric Population: The pharmacokinetics of cinacalcet have been studied in 12 paediatric patients (6-17 years) with CKD receiving dialysis following a single, oral, 15 mg dose. Mean AUC and Cmax values (23.5 (range 7.22 to 77.2) ng*hr/ml and 7.26 (range 1.80 to 17.4) ng/ml, respectively) were within approximately 30% of the means for AUC and Cmax values observed in a single study in healthy adults following a single 30 mg dose (33.6 (range 4.75 to 66.9) ng*hr/ml and 5.42 (range 1.41 to 12.7) ng/ml, respectively). Due to the limited data in paediatric subjects, the potential for higher exposures in the lighter/younger relative to heavier/older paediatric subjects for a given dose of cinacalcet cannot be excluded. The pharmacokinetics in paediatric subjects after multiple doses has not been studied.
Smoking: Clearance of cinacalcet is higher in smokers than in non-smokers, likely due to induction of CYP1A2-mediated metabolism. If a patient stops or starts smoking, cinacalcet plasma levels may change and dose adjustment may be necessary.
5.3 Preclinical safety data
Cinacalcet was not teratogenic in rabbits when given at a dose of 0.4 times, on an AUC basis, the maximum human dose for secondary HPT (180 mg daily). The non-teratogenic dose in rats was 4.4 times, on an AUC basis, the maximum dose for secondary HPT. There were no effects on fertility in males or females at exposures up to 4 times a human dose of 180 mg/day (safety margins in the small population of patients administered a maximum clinical dose of 360 mg daily would be approximately half those given above).
In pregnant rats, there were slight decreases in body weight and food consumption at the highest dose. Decreased foetal weights were seen in rats at doses where dams had severe hypocalcaemia. Cinacalcet has been shown to cross the placental barrier in rabbits.
Cinacalcet did not show any genotoxic or carcinogenic potential. Safety margins from the toxicology studies are small due to the dose-limiting hypocalcaemia observed in the animal models. Cataracts and lens opacities were observed in the repeat dose rodent toxicology and carcinogenicity studies, but were not observed in dogs or monkeys or in clinical studies where cataract formation was monitored. Cataracts are known to occur in rodents as a result of hypocalcaemia.
In in vitro studies, IC50 values for the serotonin transporter and KATP channels were found to be 7 and 12 fold greater, respectively, than the EC50 for the calcium-sensing receptor obtained under the same experimental conditions. The clinical relevance is unknown, however, the potential for cinacalcet to act on these secondary targets cannot be fully excluded.
6. Pharmaceutical particulars
6.1 List of excipients
 Tablet core
Pre-gelatinised starch (maize)
Microcrystalline cellulose
Povidone
Crospovidone
Magnesium stearate
Colloidal anhydrous silica
Tablet coat
Carnauba wax
Opadry II green:
 (Lactose monohydrate, hypromellose, titanium dioxide (E171), glycerol triacetate, FD&C Blue (E132), iron oxide yellow (E172))
Opadry clear:
 (Hypromellose, macrogol)
6.2 Incompatibilities
 Not applicable.
6.3 Shelf life
 Blister: 5 years.
Bottle: 5 years.
6.4 Special precautions for storage
 This medicinal product does not require any special storage conditions.
6.5 Nature and contents of container
 Aclar/PVC/PVAc/Aluminium blister containing 14 tablets. Pack sizes of 1 blister (14 tablets), 2 blisters (28 tablets), 6 blisters (84 tablets) per carton.
High Density Polyethylene (HDPE) bottle with a cotton coil, and a child-resistant polypropylene cap with an induction seal, packed into a carton. Each bottle contains 30 tablets.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal and other handling
No special requirements for disposal.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7. Marketing authorisation holder
Amgen Europe B.V.
Minervum 7061
4817 ZK Breda
The Netherlands
8. Marketing authorisation number(s)
EU/1/04/292/001 – carton with 14 tablets
EU/1/04/292/002 – carton with 28 tablets
EU/1/04/292/003 – carton with 84 tablets
EU/1/04/292/004 – bottle with 30 tablets
EU/1/04/292/005 – carton with 14 tablets
EU/1/04/292/006 – carton with 28 tablets
EU/1/04/292/007 – carton with 84 tablets
EU/1/04/292/008 – bottle with 30 tablets
EU/1/04/292/009 – carton with 14 tablets
EU/1/04/292/010 – carton with 28 tablets
EU/1/04/292/011 – carton with 84 tablets
EU/1/04/292/012 – bottle with 30 tablets
9. Date of first authorisation/renewal of the authorisation
Date of first authorisation: 22 October 2004
Date of latest renewal: 23 September 2009
10. Date of revision of the text
19 September 2013
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
-------------------------------------------------------
产地国家: 德国
原产地英文商品名:
MIMPARA 30mg/tablet 28tablets/bottle
原产地英文药品名:
Cinacalcet Hydrochloride
中文参考商品译名:
MIMPARA 30毫克/片 28片/瓶
中文参考药品译名:
盐酸西那卡塞
生产厂家中文参考译名:
安进公司
生产厂家英文名:
Amgen GmbH
--------------------------------------
产地国家: 德国
原产地英文商品名:
MIMPARA 60mg/tablet 28tablets/bottle
原产地英文药品名:
Cinacalcet Hydrochloride
中文参考商品译名:
MIMPARA 60毫克/片 28片/盒
中文参考药品译名:
盐酸西那卡塞
生产厂家中文参考译名:
安进公司
生产厂家英文名:
Amgen GmbH
--------------------------------------
产地国家: 德国
原产地英文商品名:
MIMPARA 90mg/tablet 28tablets/bottle
原产地英文药品名:
Cinacalcet Hydrochloride
中文参考商品译名:
MIMPARA 90毫克/片 28片/盒
中文参考药品译名:
盐酸西那卡塞
生产厂家中文参考译名:
安进公司
生产厂家英文名:
Amgen GmbH

责任编辑:admin


相关文章
REGPARA TABLETS(Cinacalcet Hydrochloride)盐酸西那卡塞片
RENAGEL Tabs(Sevelamer Hydrochloride)盐酸司维拉姆片
盐酸西那卡塞片Mimpara(Cinacalcet Hydrochloride)
盐酸西那卡塞片(Sensipar,cinacalcet,Mimpara)
盐酸西那卡塞片REGPARA(Cinacalcet Hydrochlorid,TABLETS,锐克钙)
帕米膦酸二钠滴静注射剂Aredia(Pamidronate Disodium Hydrate)
阿可达注射液AREDIA(PAMIDRONATE DISODIUM)
盐酸西那卡塞片Sensipar(Cinacalcet Tablets)
Mimpara(cinacalcet HCl)获欧盟批准上市
Sensipar(Mimpara,cinacalcet)-盐酸西那卡塞片
 

最新文章

更多

· Natpara(重组人甲状旁腺...
· Propycil Tabletten(Pr...
· Zemplar(Paricalcitol I...
· 度骨化醇注射剂|hectoro...
· 度骨化醇软胶囊|hectoro...
· 盐酸西那卡塞片|MIMPARA...
· 帕立骨化醇注射剂|ZEMPL...
· 盐酸西那卡塞片Mimpara(...
· 碘塞罗宁钠片(Liothyron...
· 碘塞罗宁钠注射液TRIOST...

推荐文章

更多

· Natpara(重组人甲状旁腺...
· Propycil Tabletten(Pr...
· Zemplar(Paricalcitol I...
· 度骨化醇注射剂|hectoro...
· 度骨化醇软胶囊|hectoro...
· 盐酸西那卡塞片|MIMPARA...
· 帕立骨化醇注射剂|ZEMPL...
· 盐酸西那卡塞片Mimpara(...
· 碘塞罗宁钠片(Liothyron...
· 碘塞罗宁钠注射液TRIOST...

热点文章

更多